Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: Results of the prospectively randomized GAIN study

Annals of Oncology

Volumn 27, Issue 11, 2016, Pages 2053-2059

  Furlanetto, Jenny ^a   Eiermann, W ^b   Marme F ^c   Reimer, T ^d   Reinisch, M ^e   Schmatloch, S ^f   Stickeler, E ^g   Thomssen, C ^h   Untch, M ⁱ   Denkert, C ^j   von Minckwitz, G ^a   Lederer, B ^a   Nekljudova, V ^a   Weber, K ^a   Loibl, S ^a   Mobus V ^k  

^a German Breast Group ^*  (Germany)

^b Inter disciplinary Oncological Center   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Department of Obstetrics and Gynecology   (Germany)

^e KLINIKEN ESSEN MITTE   (Germany)

^f Elisabeth Krankenhaus   (Germany)

^g UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^h MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

ⁱ HELIOS KLINIKUM BERLIN BUCH   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k SANOFI   (France)

more..

Author keywords

Breast cancer; Dose adjustment; Dose dense chemotherapy; Obesity; Survival; Toxicity

Indexed keywords

CAPECITABINE; CREATININE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; PEGFILGRASTIM; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ADULT; AGE; ANEMIA; ARTICLE; BILIARY TRACT DISEASE; BODY MASS; BODY SURFACE; BODY WEIGHT; BREAST CANCER; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DIZZINESS; DOSE DENSIFICATION; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART DISEASE; HOT FLUSH; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MICTURITION DISORDER; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBESITY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; BREAST TUMOR; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; FEMALE; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; BODY SURFACE AREA; BREAST NEOPLASMS; CAPECITABINE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIRUBICIN; FEBRILE NEUTROPENIA; FEMALE; HUMANS; LYMPHATIC METASTASIS; OBESITY; TAXOIDS;

EID: 85025110461     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw315     Document Type: Article

References (30)

1. WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization, 2000
2. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123 (3): 627-635
3. Ewertz M, Jensen MB, Gunnarsdóttir Ká et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011; 29(1): 25-31
4. Fontanella C, Lederer B, Gade S et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat 2015; 150(1): 127-139
5. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005; 165(11): 1267-1273
6. Rosner GL, Hargis JB, Hollis DR et al. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol 1996; 14(11): 3000-3008
7. Budman DR, Berry DA, Cirrincione CT et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998; 90(16): 1205-1211
8. Griggs JJ, Mangu PB, Anderson H et al. American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30(13): 1553-1561
9. von Minckwitz G, Möbus V, Schneeweiss A et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol 2013; 31 (28): 3531-3539
10. Moebus V, Schneeweiss A, du Bois A et al. Ten year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin, paclitaxel and cyclophosphamide) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high-risk breast cancer patients with = 4 positive lymph nodes. Cancer Res 2012; 72: S3-S4
11. Loibl S, Mueller V, von Minckwitz G et al. Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). Support Care Cancer 2011; 19(11): 1789-1795
12. Moebus V, Von Minckwitz G, Jackisch C et al. German Adjuvant Intergroup Node Positive (GAIN) study: a phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer-final efficacy analysis. J Clin Oncol 2014; 32: 5s
13. Möbus V, Conrad B, Schneeweiss A et al. Gain study: a phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with nodepositive primary breast cancer. J Clin Oncol 2009; 27: 15S
14. http://www.agoonline.de/fileadmin/downloads/leitlinien/mamma/Maerz2016/de/2016D% 2013_Adjuvante%20Strahlentherapie.pdf (6 March 2016, date last accessed)
15. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17: 863-871
16. Pai MP, Paloucek FP. The origin of the 'ideal' body weight equations. Ann Pharmacother 2000; 34(9): 1066-1069
17. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332(14): 901-906
18. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/dataand-statistics/infographic-over-50-of-people-are-overweight-or-obese-download (21 September 2015, date last accessed)
19. Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med 2005; 118: 978-980
20. Barni S, Labianca R, Agnelli G et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 2011; 9: 179
21. von Minckwitz G, Schneeweiss A, Loibl S et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014; 15(7): 747-756
22. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4(8): 1162-1170
23. Bandera EV, Lee VS, Rodriguez-Rodriguez L et al. Impact of chemotherapy dosing on ovarian cancer survival according to body mass index. JAMA Oncol 2015; 1(6): 737-745
24. Loibl S, Skacel T, Nekljudova V et al. Evaluating the impact of relative total dose intensity (RTDI) on patients' short and long-term outcome in taxane-and anthracycline-based chemotherapy of metastatic breast cancer-a pooled analysis. BMC Cancer 2011; 11: 131
25. Horowitz NS, Wright AA. Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies. Gynecol Oncol 2015; 138(1): 201-206
26. Colleoni M, Li S, Gelber RD, Price KN et al. International Breast Cancer Study Group. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 2005; 366(9491): 1108-1110
27. Hunter RJ, Navo MA, Thaker PH et al. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev 2009; 35: 69-78
28. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-231
29. Knibbe CA, Brill MJ, van Rongen A et al. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol 2015; 55: 149-167
30. Hourdequin KC, Schpero WL, McKenna DR et al. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol 2013; 24(12): 2952-2962